Observational studyCurrent oncology (Toronto, Ont.)2022

Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group.

Stefania Kokkali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.